Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Almost all prostate cancers are adenocarcinomas. Rarer types of prostate cancer include:
Small cell carcinomas
Transitional cell carcinomas
Other factors in diagnosis and treatment planning
There are additional considerations beyond type that affect recommendations your care team may make for treatment.
Tumor size offers clues about how quickly the tumor may have developed and how likely it is to spread. Larger cancers are more likely to progress to the lymph nodes.
Grade assigns a numeric value between 1 and 5, called a Gleason score, to describe how abnormal the cancer cells appear under the microscope. The the higher the number the more aggressive the cancer is. Lower numbers are usually is associated with a slower growth
We offer robust clinical trial programs for prostate cancer. These research studies evaluate new medical approaches, devices, drugs, and other treatments.
As a Stanford Health Care patient, you may be eligible to participate in open clinical trials. Open trials refer to studies currently recruiting participants or that may recruit participants in the near future. Closed trials are not currently enrolling, but similar studies may open in the future.
You can access Stanford’s expertise and compassionate care for any stage or type of prostate cancer at a location that is convenient for you. We always accept new patients, and we take many insurance plans, including Medicare and Medi-Cal.